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Understanding the impact of antimicrobial use on the emergence of resistant bacteria is
imperative to prevent its emergence. For instance, activation of the AcrAB efflux pumps
is responsible for the emergence of antimicrobial-resistant Salmonella strains. Here, we
examined the expression levels of acrB and its multiple regulator genes (RamA, SoxS,
MarA, and Rob) in 17 field isolates of S. Choleraesuis by using quantitative PCR methods.
The expression of acrB increased in eight of the field isolates (P <0.05). The expression
of acrB was associated with that of ramA in one isolate, soxS in one isolate, and both
these genes in six isolates. Thereafter, to examine the effect of selected antimicrobials
(enrofloxacin, ampicillin, oxytetracycline, kanamycin, and spectinomycin) on the expres-
sion of acrB and its regulator genes, mutants derived from five isolates of S. Choleraesuis
were selected by culture on antimicrobial-containing plates. The expression of acrB and
ramA was higher in the mutants selected using enrofloxacin (3.3–6.3- and 24.5–37.7-fold,
respectively), ampicillin (1.8–7.7- and 16.1–55.9-fold, respectively), oxytetracycline (1.7–3.3-
and 3.2–31.1-fold, respectively), and kanamycin (1.6–2.2- and 5.6–26.4-fold, respectively),
which are AcrAB substrates, than in each of the parental strains (P <0.05). In contrast,
in AcrAB substrate-selected mutants, the expression of soxS, marA, and rob remained
similar to that in parental strains. Of the four antimicrobials, the level of ramA expression
was significantly higher in the enrofloxacin- and ampicillin-selected mutants than in the
oxytetracycline- and kanamycin-selected mutants (P <0.05), whereas the expression lev-
els of acrB and multiple regulator genes in spectinomycin-selected mutants were similar
to those in each parental strain. These data suggest that exposure to antimicrobials that
are AcrAB substrates enhance the activation of the AcrAB efflux pump via RamA, but not
via SoxS, MarA, or Rob in S. Choleraesuis.
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INTRODUCTION
Salmonella enterica subspecies enterica serovar Choleraesuis is
a bacterial pathogen that causes severe diarrhea, pneumonia,
and septicemia in pigs and in elderly and immunocompromised
humans (Chiu et al., 2004). These bacteria sometimes cause
severe infections, necessitating antimicrobial treatment of affected
patients. A high rate of multidrug resistance among S. Cholerae-
suis has been reported in several countries (Lee et al., 2009; Asai
et al., 2010), raising a concern for public and animal health.
Activation of an efflux system that removes the drug from the
cell is one antimicrobial resistance mechanism in bacteria (Chen
et al., 2007; Li and Nikaido, 2009). The AcrAB-TolC system is the
main multidrug efflux system in Gram-negative bacteria (Giraud
et al., 2000). The expression level of acrAB mRNAs correlates
with efflux activities and is regulated by global regulatory pro-
teins and local repressors (Rosenberg et al., 2003; Li and Nikaido,
2004; Olliver et al., 2004; Abouzeed et al., 2008). In particular, the
expression of acrAB is regulated by the global regulators, RamA,
SoxS, MarA, and Rob (Rosenberg et al., 2003; Abouzeed et al.,
2008). Moreover, mutations within the local repressor AcrR con-
tribute to the overexpression of acrAB (Olliver et al., 2004). In S.
Typhimurium and S. Haardt, RamA mainly regulates the expres-
sion of acrAB (Figure 1; Nikaido et al., 2008; Zheng et al., 2009;
Kim and Woo, 2011). Other regulators, SoxS and MarA, are also
known to regulate acrAB expression, but the contributions of SoxS
and MarA to antimicrobial susceptibilities are lower than that of
RamA (Abouzeed et al., 2008). Little is known about Rob and its
contribution to the enhancement of AcrAB in Salmonella (Rosen-
berg et al., 2003). In S. Pullorum, the expression of acrB, which
shifts from sensitivity to resistance against bile salt (deoxycholate,
an AcrAB substrate), was independent of ramA, soxS, marA, and
rob expression (Usui et al., 2011).
We have previously recorded the various efflux activity lev-
els of S. Choleraesuis under field conditions, suggesting that
elevated efflux activities are related to the emergence of fluo-
roquinolone resistance (Usui et al., 2009). In fluoroquinolone-
selected S. Choleraesuis, efflux pumps including AcrAB were
enhanced and resulted in decreasing susceptibilities to several
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antimicrobials (Usui et al., 2010). However, little is known about
roles of regulator genes for efflux pumps in S. Choleraesuis. In
this study, we examined the expression levels of acrAB and multi-
ple regulator genes in 17 clinical swine isolates of S. Choleraesuis
FIGURE 1 | Regulation of acrAB expression by multiple regulators in
SalmonellaTyphimurium and S. Haardt. This figure was produced using
data from the literature (see main text). Functional interactions are
represented as arrows for activation/induction and as “a” for repression.
The size of arrows indicates the estimated impact.
and antimicrobial-selected mutants in order to understand the
impact of antimicrobial exposure on the efflux activities in this
organism.
MATERIALS AND METHODS
BACTERIAL STRAINS
Seventeen strains of S. Choleraesuis, obtained from differ-
ent diseased pigs between 2001 and 2005 (Asai et al., 2010),
were used in this study (Table 1). These strains com-
prised 6 nalidixic acid-resistant strains (low enrofloxacin-
accumulation), and 11 nalidixic acid-susceptible strains (two
strains: low enrofloxacin-accumulation; three strains: interme-
diate enrofloxacin-accumulation; six strains: high enrofloxacin-
accumulation) as previously recorded (Usui et al., 2009). The
intracellular concentration of enrofloxacin was significantly
lower in nalidixic acid-resistant isolates, and the nalidixic acid-
susceptible isolates ZSC-8 and 582 as compared to other suscep-
tible isolates with the exception of isolates 143, ZSC-12, and 1002
(P < 0.1; Usui et al., 2009). The intracellular enrofloxacin concen-
trations of isolates 143, ZSC-12, and 1002 were at an intermediate
level. Minimum inhibitory concentrations (MIC) of enrofloxacin,
ampicillin, oxytetracycline, and kanamycin had been determined
in our previous study (Asai et al., 2010). MIC of spectinomycin was
Table 1 | Characterization of Salmonella Choleraesuis used in this study.
Strain no. Susceptibility to nalidixic acida Enrofloxacin-accumulation mRNA expression Mutations
Categoryb MIC (mg/L)b Categoryc (ng/105cfu)c acrAd acrBd AcrRe Binding site
13-PLS-6 Resistance 256 Low 8.2 1.6±0.2* 1.8±0.2* WT WT
14-PLS-21 Resistance >512 Low 8.7 3.9±0.3* 2.7±0.2* WT WT
16-PLS-45 Resistance >512 Low 6.5 1.5±0.1* 1.9±0.3* Q78ter WT
16-PLS-46 Resistance >512 Low 6.6 2.4±0.2* 2.4±0.4* Q78ter WT
sal-1372 Resistance >512 Low 6.3 1.8±0.1* 2.2±0.2* WT WT
16-PLS-33 Resistance >512 Low 5.1 1.5±0.1* 1.9±0.2* Q78ter WT
ZSC-8 Susceptible 8 Low 8.1 1.7±0.1* 1.8±0.2* Q78ter WT
582 Susceptible 8 Low 7.2 1.4±0.1* 1.4±0.2* Q78ter WT
143 Susceptible 8 Intermediate 9.1 1.1±0.1 1.3±0.1 Q78ter WT
ZSC-12 Susceptible 4 Intermediate 9.5 1.0±0.1 1.0±0.1 Q78ter WT
1002 Susceptible 4 Intermediate 9.8 1.1±0.2 1.2±0.2 Q78ter WT
916 Susceptible 4 High 10.7 1.1±0.1 1.1±0.1 Q78ter WT
03-197-1 Susceptible 2 High 11.4 0.9±0.1 0.8±0.1 Q78ter WT
03-228-1 Susceptible 2 High 10.7 1.0±0.2 1.1±0.1 Q78ter WT
ZSC-14-1 Susceptible 4 High 11.0 0.9±0.1 1.1±0.1 Q78ter WT
ZSC-40 Susceptible 4 High 10.5 0.9±0.2 0.9±0.2 WT WT
419 Susceptible 4 High 12.7 1.0±0.2 0.9±0.1 Q78ter WT
MIC, minimum inhibitory concentration; WT, wild-type sequence.
aMIC break point of nalidixic acid is 32 mg/L.
bData from a previous report (Asai et al., 2010).
cData from a previous report (Usui et al., 2009).
dRelative expression level compared to the average for six high enrofloxacin-accumulating nalidixic acid-susceptible strains.
eQ78ter, stop codon mutation, glutamine-78-termination.
*Indicates mRNA expression is significantly higher than mRNA expression of six high enrofloxacin-accumulating nalidixic acid-susceptible strains (P<0.05).
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determined by the broth microdilution method according to CLSI
guidelines (Clinical and Laboratory Standard Institute, 2008).
LABORATORY-SELECTED MUTANTS
Five strains (582, 143, 916, 1002, and 419), susceptible to all of
the antimicrobial agents evaluated in this study, were selected as
parent strains from which mutants were isolated. Cultures grown
on agar containing various agents was employed, including three
AcrAB substrates (ampicillin, oxytetracycline, and kanamycin)
and one non-substrate (spectinomycin; Bailey et al., 2008; Ricci
and Piddock, 2009a,b). For selection of mutants, 0.1 mL of each
strain, adjusted to 108–109cfu/mL were exposed to 4×MIC of
the respective substance for each strain in the agar medium, as
described previously (Ricci and Piddock, 2009b). A single strain
was selected for each combination. In addition, as fluoroquinolone
is an AcrAB substrates, enrofloxacin-selected mutants obtained
in our previous report were used as control (Usui et al., 2010).
MICs of antimicrobials for mutants were determined as described
above.
QUANTITATIVE PCR ANALYSIS OF EXPRESSION OF 16S rRNA, acrAB,
AND MULTIPLE GLOBAL REGULATORS
To evaluate the genes conferring efflux pump activity and their
multiple global regulators, quantitative PCR was applied to the
detection and quantification of mRNAs (Usui et al., 2010, 2011).
The preparation of cDNA was performed as described by Zheng
et al. (2009), with slight modifications. In brief, extraction of
total RNA from 5 mL of bacterial suspensions was carried out
with an ISOGEN kit (Nippon Gene, Tokyo, Japan). cDNA was
synthesized from these RNA samples using the PrimeScript RT
reagent kit (TaKaRa, Shiga, Japan). Quantitative PCR was per-
formed with SYBR premix EX TaqII (TaKaRa) on a One Step
real-time system (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. The oligonucleotide
primers used for the detection of cDNA are listed in Table 2.
The yields of amplicons from acrA, acrB, ramA, soxS, marA,
and rob were normalized to those originating from 16S rRNA.
Within bacterial cells, 16S rRNA was assumed to be transcribed
at a constant rate throughout the growth conditions used in this
study.
After normalization to the levels of 16S rRNA, gene expres-
sion was compared with the average values for the six high
enrofloxacin-accumulating susceptible strains.
acrR DNA SEQUENCE ANALYSIS
Mutations in the local repressor gene, acrR, and the regulator-
binding site were detected by direct DNA sequencing, using pre-
viously reported primer sets (Zheng et al., 2009). Amplification
of the gene and purification of the resulting amplicon were
performed as described before (Zheng et al., 2009). Nucleotide
Table 2 | Primers used in this study.
Primer name Sequence (5′–3′) Reference
acrA-F AAAACGGCAAAGCGAAGGT Usui et al. (2011)
acrA-R GTACCGGACTGCGGGAATT Usui et al. (2011)
acrB-rt1 GGCATTGGGTATGACTGGAC Zheng et al. (2009)
acrB-rt2 GCATTACGGAGAACGGGATAG Zheng et al. (2009)
ramA-rt1 TTTCCGCTCAGGTTATCGAC Zheng et al. (2009)
ramA-rt2 CGGGCAATATCATCAATACG Zheng et al. (2009)
soxS-rt1 AAATCGGGCTACTCCAAG Zheng et al. (2009)
soxS-rt2 TACTCGCCTAATGTTTGATG Zheng et al. (2009)
marA-rt1 ATTCTCTATCTGGCGGAAC Zheng et al. (2009)
marA-rt2 CGGGTCAATGTTTGCTGTG Zheng et al. (2009)
robA-rt1 TATTCCGCCAGTGCTTTATG Zheng et al. (2009)
robA-rt2 CCTGCTCATCGTCTTTCTCC Zheng et al. (2009)
16S rRNA-F CCAGCAGCCGCGGTAAT Usui et al. (2010)
16S rRNA-R TTTACGCCCAGTAATTCCGATT Usui et al. (2010)
FIGURE 2 | Expression of multiple regulator genes in field isolates
of S. Choleraesuis. The expression of multiple regulator genes in
resistant strains and low enrofloxacin-accumulating nalidixic
acid-susceptible strains was compared to the average expression of
the corresponding genes in high enrofloxacin-accumulating nalidixic
acid-susceptible strains (n=6). Horizontal line indicates the average
gene expression in the six susceptible strains, which expressions were
set to be 1.0. *Indicates that mRNA expression is significantly higher in
a strain compared to mRNA expression in the six susceptible strains
(P < 0.05).
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Table 3 |The MICs of several antimicrobials and gene expressions of acrB and multiple regulator genes in laboratory-selected mutants.
Strain no. Selecting
agenta
MIC (mg/L) mRNA expressionc
Enrofloxacin
(2)b
Ampicillin
(32)b
Oxytetracycline
(16)b
Kanamycin
(64)b
Spectinomycin
(128)b
acrB ramA soxS marA rob
582 0.0625 1 2 2 32 1.4 1.6 1.5 1.1 1.0
582/E Enrofloxacin 0.25 4 4 2 32 6.9 39.2 0.8 1.2 0.6
582/A Ampicillin 0.25 4 8 2 32 7.7 89.5 0.3 1.2 0.8
582/O Oxytetracycline 0.125 4 4 2 32 4.2 9.5 0.3 1.1 0.9
582/K Kanamycin 0.125 2 4 4 32 3.1 9.0 0.5 1.3 0.6
582/S Spectinomycin 0.0625 1 2 2 128 1.7 1.4 1.5 1.2 0.8
143 0.0625 1 2 2 32 1.3 1.2 1.2 1.1 1.0
143E Enrofloxacin 0.25 4 4 2 32 4.3 45.2 0.6 0.9 0.7
143/A Ampicillin 0.125 4 4 2 32 2.9 38.8 0.1 0.7 0.5
143/O Oxytetracycline 0.0625 2 8 2 32 2.2 10.2 1.3 1.2 0.3
143/K Kanamycin 0.0625 2 4 8 32 2.1 9.3 1.1 1.2 0.4
143/S Spectinomycin 0.0625 1 2 2 128 1.6 0.9 0.9 0.7 0.7
1002 0.0625 1 2 2 32 1.2 1.0 0.8 1.0 1.0
1002/E Enrofloxacin 0.25 4 4 2 32 8.0 29.8 0.1 1.2 1.0
1002/A Ampicillin 0.125 4 2 2 32 2.4 16.1 0.1 0.3 0.5
1002/O Oxytetracycline 0.125 2 8 2 32 2.2 14.7 0.2 1.2 0.9
1002/K Kanamycin 0.125 2 4 4 32 2.4 14.2 0.3 1.0 0.9
1002/S Spectinomycin 0.0625 1 2 2 128 1.1 1.4 0.4 1.1 0.9
916* 0.0625 1 2 2 32 1.1 1.1 0.8 0.9 0.9
916/E Enrofloxacin 0.5 4 4 2 32 7.4 34.2 0.4 0.8 0.9
916/A Ampicillin 0.25 4 4 2 32 8.5 58.2 0.1 0.9 0.8
916/O Oxytetracycline 0.0625 1 4 2 32 2.2 3.5 0.2 1.0 0.9
916/K Kanamycin 0.0625 1 4 8 32 2.2 6.5 0.1 1.0 0.6
916/S Spectinomycin 0.0625 1 2 2 128 1.2 0.6 0.2 0.7 0.6
419* 0.0625 4 2 2 32 0.9 0.7 1.0 1.0 1.0
419/E Enrofloxacin 0.25 16 4 2 32 5.7 24.2 0.2 1.7 0.8
419/A Ampicillin 0.0625 8 2 2 32 1.6 32.5 0.3 0.7 0.9
419/O Oxytetracycline 0.125 8 8 2 32 3.0 21.8 0.8 3.4 1.6
419/K Kanamycin 0.0625 8 4 8 32 1.5 18.5 0.3 1.1 0.9
419/S Spectinomycin 0.0625 4 2 2 128 0.9 1.1 0.4 2.1 1.2
03-197-1* 0.0625 >128 256 2 32 0.8 1.1 1.3 1.2 1.2
03-228-1* 0.0625 1 256 8 32 1.1 1.1 1.0 0.9 0.9
ZSC-14-1* 0.0625 1 256 2 32 1.1 1.0 1.0 1.0 0.8
ZSC-40* 0.0625 >128 256 2 32 0.9 0.8 0.8 1.1 0.9
MIC, minimum inhibitory concentration.
aMutants were selected by exposing to fourth the MIC of the antimicrobials for each susceptible strain.
bMIC data of antimicrobials except for spectinomycin in parental strains from a previous report (Asai et al., 2010). Parenthesis indicates break points.
cRelative expression level of acrB and multiple regulator genes compared to average of six high accumulation susceptible strains represented as asterisks.
sequences were determined using a BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) with a 3130 Genetic Analyzer
(Applied Biosystems).
STATISTICAL ANALYSIS
Student’s t -test was used to compare results between and within
experiments. P-values< 0.05 were considered significant.
RESULTS
RELATIONSHIP BETWEEN THE ENHANCEMENT OF EFFLUX PUMPS AND
THE EXPRESSION OF acrAB
Expression of acrA and acrB in the six resistant strains and in
the two low enrofloxacin-accumulation nalidixic acid-susceptible
strains was significantly higher than that in the other susceptible
strains (P < 0.05; Table 1). Expression levels of acrB correlated
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significantly with those of acrA in this study (correlation coeffi-
cient: 0.89).
RELATIONSHIP BETWEEN INCREASED EXPRESSION OF acrB AND
GLOBAL REGULATORS
Of the eight strains with a high acrB expression level, six strains
showed higher levels of both ramA and soxS expression compared
with the average values for the six high accumulating suscepti-
ble strains (P < 0.05; Figure 2). The remaining strains showed
a higher level of ramA or soxS expression (P < 0.05): the 14-
PLS-21 strain showed only a higher expression level of ramA
(107.1-fold± 42.0-fold), while the ZSC-8 strain showed only a
higher expression level of soxS (17.4-fold± 2.7-fold). Neither the
expression of marA nor that of rob changed in any of the strains
tested.
SEQUENCING OF THE LOCAL REPRESSOR GENE acrR AND OF THE
REGULATOR-BINDING SITE
A stop codon mutation in AcrR (glutamine-78-to-terminal;
Q78ter) was found in 13 strains (Table 1). No significant rela-
tionship was found between the Q78ter stop codon mutation
in AcrR and the expression of acrB. None of the strains tested
had a point mutation in the regulator-binding site, which affects
the acrB expression, previously determined using the S. serovar
Typhimurium strain BN18 (Olliver et al., 2004).
GENE EXPRESSION IN LABORATORY-SELECTED MUTANTS
Expression levels of both acrB and ramA increased significantly
in AcrAB substrate-selected mutants compared to these levels in
parental strains (P < 0.05; Table 3). Among four AcrAB substrates,
a higher level of ramA expression was observed in the enrofloxacin-
and ampicillin-selected mutants than in the oxytetracycline- and
kanamycin-selected mutants (P < 0.05). In contrast, the expres-
sion of soxS decreased significantly in AcrAB substrate-selected
mutants compared to that in parental strains (P < 0.05; Table 3).
MICs of AcrAB substrates were increased in AcrAB substrate-
selected mutants as compared with those in the parental strains
(Table 3).
Expression of acrB and multiple regulator genes remained sta-
ble in spectinomycin-selected mutants. In spectinomycin-selected
mutants, MICs of AcrAB substrates were of the same level as
compared with those in the parental strains (Table 3).
DISCUSSION
The current study showed that the expression of ramA and/or
soxS was associated with acrAB overexpression in field iso-
lates of S. Choleraesuis. In this study, expression of ramA, but
not soxS, marA, or rob, was enhanced in laboratory-derived
S. Choleraesuis mutants selected using antimicrobials that are
AcrAB substrates. Several previous studies have reported that
ramA, but not soxS, is involved in activation of the AcrAB-
TolC system in S. Typhimurium (Ricci et al., 2006; Bailey et al.,
2008; Zheng et al., 2009). Interestingly, in this study, soxS expres-
sion was downregulated in AcrAB substrate-selected mutants
of S. Choleraesuis. In addition, enrofloxacin- and ampicillin-
selected mutants derived from the ZSC-8 strain with a high
level of soxS expression, showed increased expression of ramA,
but not of soxS (data not shown). Several studies have sug-
gested that increased expression of ramA downregulates soxS
expression (Nikaido et al., 2008; O’Regan et al., 2009). These
results suggest that the acrA and acrB expression in antimicrobial-
selected mutants of S. Choleraesuis were dependent on ramA
expression.
The present study showed that increased levels of both ramA
and soxS expression were demonstrated by some field isolates of
S. Choleraesuis upon activation of the AcrAB-TolC system. There
was a marked difference in soxS expression between the field iso-
lates and the laboratory-derived strains. As all of the strains used
in this study were isolated from diseased pigs, these isolates would
have been exposed to antimicrobials and disinfectants used in dis-
ease treatment and hygiene management. This suggests that the
resistance in some field isolates was mediated through a differ-
ent mechanism, and therefore could have arisen from a different
selective pressure.
Activation of the AcrAB efflux pump is responsible for the
emergence of fluoroquinolone-resistant Salmonella strains (Ricci
et al., 2006; Usui et al., 2009). In Japan, the description of vet-
erinary fluoroquinolone drugs includes an explanation that the
drug is considered as a second-line drug. In the AcrAB substrate-
selected mutants, the level of acrB expression generally increased,
depending on ramA expression. It is possible that the use of an
AcrAB substrate as a first-line drug crucially selects strains of S.
Choleraesuis with activated AcrAB efflux systems. Among AcrAB
substrates used in this study, the degree of acrB expression may
be different due to exposure to the various antimicrobial agents.
Therefore, the antimicrobial class used as first-line drugs may be
associated with the frequency of fluoroquinolone resistance in bac-
terial strains. Further studies are needed in order to clarify the
effects of each antimicrobial on acrB expression in these bacteria.
In conclusion, the AcrAB-TolC efflux system in field isolates
of S. Choleraesuis is likely regulated by external factors in the
environment, such as antimicrobials and drug residues via ramA
and soxS. In particular, exposure of AcrAB substrates enhances
activation of AcrAB via RamA in S. Choleraesuis.
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